Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer

Prabir K. Chakravarty, Alan Alfieri, Elaine K. Thomas, Vivek Beri, Kathryn E. Tanaka, Bhadrasain Vikram, Chandan Guha

Research output: Contribution to journalArticle

136 Scopus citations

Abstract

An ineffective tumor-specific immune response from inadequate/incompetent antigen presentation could contribute to the failure in tumor control and its dissemination. Dendritic cells (DCs) have been shown to present antigen from apoptotic cells. We hypothesized that Flt3-ligand (Flt3L) therapy, which expands DCs in vivo, in combination with local tumor radiotherapy (RT), should improve antigen presentation from dying, irradiated tumor cells. RT + Flt3L reduced pulmonary metastases in a murine model of Lewis lung carcinoma and significantly improved survival in C57B1/6 mice with established footpad tumors. Mice treated with Flt3L alone showed delayed tumor growth but eventually succumbed to tumor progression. The combination therapy of RT + Flt3L failed to impact survival in immunodeficient athymic mice, implicating the role of T cells in prolonging survival. These results support an attractive strategy of sequential RT and immunotherapy with Flt3L to enhance tumor antigen presentation, which may produce therapeutic responses against disseminated cancer and improvement in survival.

Original languageEnglish (US)
Pages (from-to)6028-6032
Number of pages5
JournalCancer Research
Volume59
Issue number24
StatePublished - Dec 15 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Chakravarty, P. K., Alfieri, A., Thomas, E. K., Beri, V., Tanaka, K. E., Vikram, B., & Guha, C. (1999). Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Research, 59(24), 6028-6032.